<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996656</url>
  </required_header>
  <id_info>
    <org_study_id>PAPA</org_study_id>
    <nct_id>NCT02996656</nct_id>
  </id_info>
  <brief_title>Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery</brief_title>
  <acronym>PAPA</acronym>
  <official_title>Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery: A Double Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tornier, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital du Sacre-Coeur de Montreal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction
      for all orthopaedic procedure with implantation of internal fixation device. With the
      increasing rate of identified P. acnes shoulder surgery infection despite the use of
      recommended skin preparation and preoperative prophylactic antibiotics, a question arises; Is
      Cefazolin the most effective prophylactic antibiotic for shoulder surgery? The objective of
      this study is to determine if Ceftriaxone is superior to Cefazolin as a prophylactic
      antibiotic for skin colonization with P. acnes in primary shoulder surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded randomized clinical trial comparing two different prophylactic
      antibiotics used for primary open shoulder surgery. The participants are volunteer patients
      scheduled for a primary open elective or trauma shoulder surgery. Patients with positive MRSA
      screening test will be excluded from the randomised study as they will receive vancomycin for
      prophylaxis. If they accept to participate, they will be included in the observational MRSA+
      arm. The investigators will take from the participants the same data as the randomised
      patients and the investigators will take biopsies.

      4 equals group will be form: Female-elective: 22 envelops, 11 cefazolin, 11 ceftriaxone in a
      randomly order Female-trauma: 22 envelops, 11 cefazolin, 11 ceftriaxone in a randomly order
      Male-elective: 22 envelops, 11 cefazolin, 11 ceftriaxone in a randomly order Male-trauma: 22
      envelops, 11 cefazolin, 11 ceftriaxone in a randomly order The surgeons, anesthesiologist,
      patients and laboratory technician, microbiologist will be blinded to the antibiotics
      received by the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Biopsy</measure>
    <time_frame>At the initial surgery</time_frame>
    <description>Number of bacteria identified in five skin biopsies taken at the surgical site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRSA observance</measure>
    <time_frame>1 year following the surgery</time_frame>
    <description>Observe the patients from de MRSA group which will be receiving Vancomycin as prophylactic antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>1 year following the surgery</time_frame>
    <description>Assessing the appearance of C Difficile infection at 1 year post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection #2</measure>
    <time_frame>1 year following the surgery</time_frame>
    <description>Assessing the appearance of resistant pathogens colonization (MRSA, VRE, Multiresistant Gram negative Bacillus) 1 year post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection #3</measure>
    <time_frame>1 year following the surgery</time_frame>
    <description>Follow all the participants for one year to observe superficial tissue infection (as defined by the infection prevention team of Montreal Sacre-Coeur Hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection #4</measure>
    <time_frame>1 year following the surgery</time_frame>
    <description>Follow all the participants for one year to observe deep tissue infection (as defined by the infection prevention team of Montreal Sacre-Coeur Hospital)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Propionibacterium Infection</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Antibiotic that will be give before a Trauma or elective open shoulder surgery</description>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>Antibiotic that will be give before a Trauma or elective open shoulder surgery</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Male or female

          -  Presenting normal skin on the shoulder aria

        Exclusion Criteria:

          -  Used antibiotics or treated their skin with antibiotic gel, alcohol gel or cream or
             acne treatment in the last three months

          -  Active infection at the surgical site or anywhere

          -  Affected shoulder previously received radiotherapy

          -  Allergic to one of the antimicrobial prophylaxis used

          -  Open fracture

          -  Life threatening or a limb threatening pathology

          -  Liver or kidney failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Rouleau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Rouleau, MD</last_name>
    <phone>514-338-2222</phone>
    <phone_ext>3427</phone_ext>
    <email>dominique_rouleau@yahoo.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karine Tardif</last_name>
    <phone>514-338-2222</phone>
    <phone_ext>3465</phone_ext>
    <email>karinetardif2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Rouleau</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>2050</phone_ext>
      <email>dominique_rouleau@yahoo.ca</email>
    </contact>
    <contact_backup>
      <last_name>Karine Tardif</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3465</phone_ext>
      <email>karinetardif2@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Montréal</investigator_affiliation>
    <investigator_full_name>Dominique Rouleau</investigator_full_name>
    <investigator_title>Orthopaedic surgeon</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

